Stay updated with breaking news from Diffuse Largeb Cell Lymphoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone, resulting in median overall survival of...
NEW YORK--(BUSINESS WIRE)--Jun 1, 2024--
Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.
Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell lymphoma (DLBCL).
/PRNewswire/ -- In the era medical breakthroughs, advancements in Diffuse Large B-Cell Lymphoma (DLBCL) therapeutics stand out as a beacon of hope. The diffuse...